Cleerly – Weekly Recap

Cleerly, an AI-powered cardiac imaging company, reported a week of product enhancements, growing clinical interest, and strengthening validation for its coronary CT analysis platform. The company unveiled its new Cleerly PREVIEW feature, designed to prioritize coronary CT angiography studies by surfacing stenosis severity, exact diameter values, and locations aligned with reimbursement thresholds.

The PREVIEW workflow aims to bring clinically relevant information earlier into radiology and cardiology decision-making, with the goal of improving operational efficiency and interpretation consistency. This upgrade deepens Cleerly’s focus on coronary artery disease severity and decision support, potentially enhancing its appeal to hospitals and imaging centers that seek integrated, billing-aware tools.

Cleerly also highlighted fresh data from the INVICTUS registry, showing 94.4% agreement between its AI-based quantitative coronary CT technology and intravascular ultrasound, a gold-standard invasive modality for plaque quantification. The multi-center nature of the registry, spanning 17 sites, supports the generalizability of these findings and positions AI-QCT as a viable, less invasive alternative for detailed plaque characterization.

In parallel, the company underscored improving reimbursement visibility, citing a new Category I CPT code and expanding insurance coverage for its technology. These developments point to a clearer payment pathway for AI-enabled coronary CT analysis, which may support broader clinical adoption as cardiology providers gain confidence in both the evidence base and economic rationale.

Cleerly maintained a strong presence at the American College of Cardiology’s ACC.26 conference, showcasing live demonstrations of its AI platform and hosting sessions at Booth #1645. The company engaged cardiologists, healthcare decision-makers, and thought leaders with 3D coronary models and color-coded plaque maps intended to enhance coronary CT angiography and inform treatment decisions.

Conference engagement and live demos at ACC.26 reinforced growing interest in AI-driven plaque analysis and advanced cardiac imaging among clinicians. While no new contracts or financial metrics were disclosed, the combination of workflow-focused upgrades, robust validation data, and improving reimbursement dynamics supports Cleerly’s positioning for future growth in AI-enabled cardiovascular diagnostics.

Overall, the week reflected continued momentum for Cleerly as it integrates deeper into cardiology workflows, strengthens clinical credibility, and capitalizes on emerging payer support to advance adoption of its AI cardiac imaging platform.